In the Phase 2 trial, the most common adverse events were gastrointestinal: nausea (up to 25.6% at higher doses), diarrhea (up to 22.0%), vomiting (up to 12.2%), and constipation (up to 11.0%)
2) Glycaemic control endpoints in type 2 diabetes research protocols Retatrutide has also been evaluated in a phase 2 type 2 diabetes trial (The Lancet) that measured: HbA1c change at 24 weeks body weight change at 24 weeks adverse events and discontinuations within the protocol The paper reports dose dependent improvements in both glycaemic and weight outcomes in the trial setting, which is why retatrutide is often discussed as a next generation metabolic peptide for integrated glycaemic and weight endpoints in published clinical research
CKD affects 20%-55% of MASLD patients and shares pathogenic mechanisms with MASLD through insulin resistance, oxidative stress, and systemic inflammation [15]
In the future, Retatrutide may be considered for individuals who meet specific health criteria, such as those living with obesity or weight-related conditions, but suitability would depend on personal medical factors
12 Of particular interest, a 20-week research trial involving nondiabetic patients with a mean body mass index of 30 to 40 kg/m 2 at baseline compared the weight loss effects of liraglutide versus orlistat 120 mg three times daily or placebo
When to choose the conservative schedule Choose the 6-week schedule if any of these apply to you: Previous strong GI reactions to GLP-1 agonists like semaglutide or tirzepatide History of IBS, GERD, or other chronic digestive conditions BMI under 30 (lower body mass can increase sensitivity to fixed doses) Current use of other medications that affect gastric motility First-time use of any GLP receptor agonist The research is clear on this point
